Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.

[1]  K. Kimura,et al.  ANP is cleared much faster than BNP in patients with congestive heart failure , 2007, European Journal of Clinical Pharmacology.

[2]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[3]  J. Struck,et al.  Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. , 2007, Journal of cardiac failure.

[4]  D. Mark,et al.  Natriuretic peptides in the diagnosis and management of heart failure , 2006, Canadian Medical Association Journal.

[5]  J. Salonen,et al.  Clinical Research Prevention and Epidemiology Plasma N-terminal Fragments of Natriuretic Propeptides Predict the Risk of Cardiovascular Events and Mortality in Middle-aged Men , 2022 .

[6]  R. Rodeheffer,et al.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.

[7]  D. Lloyd‐Jones,et al.  Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.

[8]  C. Price,et al.  B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  C. Hengstenberg,et al.  Effect of Compensated Renal Dysfunction on Approved Heart Failure Markers: Direct Comparison of Brain Natriuretic Peptide (BNP) and N-Terminal Pro-BNP , 2005, Hypertension.

[10]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[11]  O. Vuolteenaho,et al.  Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. , 2004, Clinical chemistry.

[12]  I. Squire,et al.  N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. , 2004, Clinical science.

[13]  K. Bailey,et al.  Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study , 2004, Circulation.

[14]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[15]  M. Kurabayashi,et al.  Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction , 2003, Heart.

[16]  Georg Heinze,et al.  Comparing the importance of prognostic factors in Cox and logistic regression using SAS , 2003, Comput. Methods Programs Biomed..

[17]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[18]  M. Davies,et al.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations , 2002, BMJ : British Medical Journal.

[19]  J. Mair,et al.  Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[20]  U. Schmidt,et al.  Acid Prohormone Sequence Determines Size, Shape, and Docking of Secretory Vesicles in Atrial Myocytes , 2001, Circulation research.

[21]  J. Wijbenga,et al.  Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice. , 1999, European heart journal.

[22]  D. Barnett,et al.  Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. , 1999, Clinical science.

[23]  E. Espiner,et al.  The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. , 1999, Biochemical and biophysical research communications.

[24]  D. Schocken,et al.  Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. , 1997, Cardiovascular research.

[25]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[26]  K. Dickstein,et al.  Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. , 1997, Journal of cardiac failure.

[27]  K. Bailey,et al.  Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. , 1996, Hypertension.

[28]  K. Dickstein,et al.  Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. , 1995, The American journal of cardiology.

[29]  C. Lang,et al.  Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. , 1994, British heart journal.

[30]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[31]  J. Shaffer.  Modified Sequentially Rejective Multiple Test Procedures , 1986 .

[32]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[33]  J. Struck,et al.  Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. , 2004, Clinical chemistry.

[34]  I. Squire,et al.  N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. , 2004, Clinical science.